neutral: the evidence is mixed or thin. that is a useful answer too. medium conviction: a reasonable case, resting on fewer or partly second-hand sources.
- the evidence, in short
Dr. Reddy's consolidated revenues for Q2FY27 were ₹86,708 Mn, down 1.5% YoY and up 7.4% QoQ.
“Particulars Q2FY27 H1FY27 Revenues ₹ 86,708 Mn ₹ 167,413 Mn [Down: 1.5% YoY; Up 7.4% QoQ]”www.sec.gov
- the main risk
North America revenue was ₹24,890 Mn in Q2FY27, against ₹32,408 Mn in Q2FY26.
“Particulars Q2FY27 Q2FY26 YoY Q1FY27 QoQ (₹) (₹) Gr % (₹) Gr% Global Generics 77,927 78,498 (1 ) 71,993 8 North America 24,890 32,408 (23 ) 22,048 13”www.sec.gov
in plain words
Dr. Reddy's consolidated revenues for Q2FY27 were ₹86,708 Mn, down 1.5% compared with the same period a year earlier and up 7.4% compared with the previous quarter. North America revenue was ₹24,890 Mn in Q2FY27, against ₹32,408 Mn in Q2FY26. Gross margin was 52.1% in Q2FY27, compared with 54.7% in Q2FY26.
what the evidence shows
Dr. Reddy's consolidated revenues for Q2FY27 were ₹86,708 Mn, down 1.5% YoY and up 7.4% QoQ.
“Particulars Q2FY27 H1FY27 Revenues ₹ 86,708 Mn ₹ 167,413 Mn [Down: 1.5% YoY; Up 7.4% QoQ]”www.sec.gov
Branded businesses, namely India, Emerging Markets and the acquired consumer health portfolio in Nicotine Replacement Therapy, accounted for 53% of Q2FY27 revenues.
“Branded businesses, namely India, Emerging Markets and the acquired consumer health portfolio in Nicotine Replacement Therapy, account for 53% of Q2FY27 revenues”www.sec.gov
what could go wrong
North America revenue was ₹24,890 Mn in Q2FY27, against ₹32,408 Mn in Q2FY26.
“Particulars Q2FY27 Q2FY26 YoY Q1FY27 QoQ (₹) (₹) Gr % (₹) Gr% Global Generics 77,927 78,498 (1 ) 71,993 8 North America 24,890 32,408 (23 ) 22,048 13”www.sec.gov
Gross margin was 52.1% in Q2FY27, compared with 54.7% in Q2FY26.
“Particulars Q2FY27 H1FY27 Revenues ₹ 86,708 Mn ₹ 167,413 Mn [Down: 1.5% YoY; Up 7.4% QoQ] [Down: 3.5% YoY] Gross Margin 52.1% 49.4% [Q2FY26: 54.7%; Q1FY27: 46.5%]”www.sec.gov
Q1FY27 results were impacted by a ₹2,397 Mn provision towards inventory and associated costs related to semaglutide's active pharmaceutical ingredient.
“Q1FY27 results were impacted due to a ₹2,397 Mn provision towards inventory and associated costs related to semaglutide’s active pharmaceutical ingredient”www.sec.gov
price and valuation facts
- Closed 0.4% below its 52-week closing high.
- Last close ₹1,380 sits 98% of the way from the 52-week closing low (₹1,135.65) to the high (₹1,386).
- Its largest fall from a peak in the last year was 17.5% (maximum drawdown).
- P/E of 118.56x (standalone) is 81% above the median of its BSE 500 industry peers (sector peers when the industry has fewer than four).
- Annualised volatility over 3 months is 22.0%, lower than 92% of the BSE 500 scrips Dalal tracks.
- Median daily BSE traded value: ₹7.48 crore over 60 days.
dalal's own computed data (from exchange prices and bse fundamentals), not from the documents above. as of 16 nov 2026.
what is coming up
Brazil's National Health Surveillance Agency (ANVISA) granted Dr. Reddy's marketing authorization for generic semaglutide injection.
“Brazil’s National Health Surveillance Agency (ANVISA) has granted marketing authorization for generic semaglutide injection”Dr Reddys Laboratories Ltd: Announcement under Regulation 30 (LODR)-Press Release / Media Release
what would change the view
the view rests on these. if they stop being true, so does the view.
The USFDA classified the inspection outcome at the FTO-SEZ Process Unit-02 in Srikakulam, Andhra Pradesh as 'Voluntary Action Indicated (VAI)'.
“FTO-SEZ Process Unit-02, Srikakulam, Andhra Pradesh. We wish to inform you that the USFDA has classified the inspection outcome as ‘Voluntary Action Indicated (VAI)’”Dr Reddys Laboratories Ltd: Disclosure Under Regulation 30 Of SEBI (LODR) Regulations, 2015
the numbers
computed by dalal when the note was written.
price
- last close
- ₹1,380.00
- 1-day change
- 0.22%
- 52-week high (closing basis)
- ₹1,386.00
- 52-week low (closing basis)
- ₹1,135.65
- 52-week high (BSE, adjusted)
- ₹1,414.40
- 52-week low (BSE, adjusted)
- ₹1,080.05
as of 16 nov 2026
returns
- 1-week return
- −0.36%
- 1-month return
- 12.03%
- 3-month return
- 15.77%
- 6-month return
- 3.65%
- 12-month return
- 10.85%
- 3-month return relative to SENSEX
- 9.60%
- 6-month return relative to SENSEX
- −4.92%
- 12-month return relative to SENSEX
- 14.17%
as of 16 nov 2026
risk
- annualised volatility (3 months)
- 22.03%
- maximum drawdown (1 year)
- −17.49%
- distance from 52-week closing high
- −0.43%
- 5-day vs 60-day BSE volume
- 0.65×
as of 16 nov 2026
valuation
- P/E (standalone)
- 118.56×
- P/E (consolidated)
- 41.74×
- P/B
- 4.28×
- EPS (standalone)
- ₹11.64
- EPS (consolidated)
- ₹33.06
- P/E relative to industry median
- 1.81×
as of 16 nov 2026
quality
- return on equity
- 3.61%
- operating margin
- 23.54%
- net margin
- 12.49%
as of 16 nov 2026
size & liquidity
- median daily BSE traded value (60 days)
- ₹7 cr
- market capitalisation
- ₹1,15,262 cr
as of 16 nov 2026
latest results (standalone)
- revenue, standalone (Sep-26)
- ₹5,573 cr
- net profit, standalone (Sep-26)
- ₹696 cr
- EPS, standalone (Sep-26)
- ₹8.35
- operating margin, standalone (Sep-26)
- 23.54%
- revenue, standalone (Jun-26)
- ₹5,137 cr
- net profit, standalone (Jun-26)
- ₹405 cr
- EPS, standalone (Jun-26)
- ₹4.86
- operating margin, standalone (Jun-26)
- 17.28%
- revenue change Jun-26 → Sep-26
- 8.49%
- net profit change Jun-26 → Sep-26
- 71.93%
as of 14 nov 2026
dalal scores
- daily score
- 59/100
- monthly score
- 99/100
- six-month score
- 54/100
- long-term score
- 65/100
as of 16 nov 2026
not available: next results board meeting; days since last results filing.
P/E: the share price divided by the profit per share over the last year · market cap: the total value of all of a company’s shares at the current share price · Sensex: the main index of BSE, tracking the share prices of a fixed group of large companies. fundamentals from bse are standalone figures. scores are percentile ranks across the bse 500 (90 = better than 90% of them on that horizon’s recipe). 7 statements passed dalal’s source checks. 3 did not and are not shown.
pick history
every time it was listed, and how it went.
never on a list so far.
in the knowledge base
the latest filings and news.
- www.sec.govwebsec.gov· undated(opens the source in a new tab)
- Dr Reddys Laboratories Ltd: Disclosure Under Regulation 30 Of SEBI (LODR) Regulations, 2015filingbse· 14 nov 2026(opens the source in a new tab)
- Dr Reddys Laboratories Ltdnewszee business· 13 nov 2026(opens the source in a new tab)
- Dr Reddys Laboratories Ltd: Announcement under Regulation 30 (LODR)-Newspaper Publicationfilingbse· 11 nov 2026(opens the source in a new tab)
- Dr Reddys Laboratories Ltd: Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimationfilingbse· 10 nov 2026(opens the source in a new tab)
- Dr Reddys Laboratories Ltd: Announcement under Regulation 30 (LODR)-Press Release / Media Releasefilingbse· 5 nov 2026(opens the source in a new tab)
- Dr Reddys Laboratories Ltd: Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPSfilingbse· 4 nov 2026(opens the source in a new tab)
- Dr Reddys Laboratories Ltd: Clarification-Disclosure Under Regulation 30 Of SEBI (LODR) Regulations, 2015filingbse· 4 nov 2026(opens the source in a new tab)
- Dr Reddys Laboratories Ltd: Clarification sought from Dr Reddys Laboratories Ltdfilingbse· 3 nov 2026(opens the source in a new tab)
- Dr Reddys Laboratories Upgraded to Hold on Technical Improvement and Market Resiliencenewsmarketsmojo· 3 nov 2026(opens the source in a new tab)
research ideas and things to consider, not personalised investment advice. every statement links to the filing or article it came from; numbers are computed by dalal from exchange data with their dates. ideas can and do lose money: the track record shows every pick, losers included. decide based on your own situation.